310,000 Orion A-shares converted into B-shares

 

ORION CORPORATION    STOCK EXCHANGE RELEASE 4 SEPTEMBER 2014 at 8.45 a.m. EEST              

310,000 Orion A-shares converted into B-shares
In accordance with Section 3 of the Articles of Association of Orion Corporation, 310,000 A-shares have been converted into 310,000  B-shares. The conversion has been entered into the Trade Register on 4 September 2014.
The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 41,062,816 A-shares and  100,195,012 B-shares.

Orion Corporation  

Olli Huotari SVP, Corporate Functions

Jari Karlson CFO

                                                   

                                                                

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2013 amounted to EUR 1,007 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.